mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse

Authors

  • Jeremie Neasta,

    1. Department of Neurology, University of California, San Francisco, California, USA
    2. The Gallo Research Center, University of California, San Francisco, California, USA
    Search for more papers by this author
  • Segev Barak,

    1. Department of Neurology, University of California, San Francisco, California, USA
    2. The Gallo Research Center, University of California, San Francisco, California, USA
    Current affiliation:
    1. School of Psychological Sciences and the Sagol School of Neuroscience, Tel Aviv University, Israel
    Search for more papers by this author
  • Sami Ben Hamida,

    1. Department of Neurology, University of California, San Francisco, California, USA
    2. The Gallo Research Center, University of California, San Francisco, California, USA
    Current affiliation:
    1. Departement de Medecine Translationnelle et Neurogenetique, Institut de Biologie Moleculaire et Cellulaire, Cedex, France
    Search for more papers by this author
  • Dorit Ron

    Corresponding author
    1. Department of Neurology, University of California, San Francisco, California, USA
    2. The Gallo Research Center, University of California, San Francisco, California, USA
    • Address correspondence and reprint requests to Dorit Ron, 675 Nelson Rising Lane, BOX 0663, San Francisco, CA 94143-0663, USA. E-mail: dorit.ron@ucsf.edu

    Search for more papers by this author

Abstract

The mammalian (or mechanistic) target of rapamycin (mTOR) complex 1 (mTORC1) is a serine and threonine kinase that regulates cell growth, survival, and proliferation. mTORC1 is a master controller of the translation of a subset of mRNAs. In the central nervous system mTORC1 plays a crucial role in mechanisms underlying learning and memory by controlling synaptic protein synthesis. Here, we review recent evidence suggesting that the mTORC1 signaling pathway promotes neuroadaptations following exposure to a diverse group of drugs of abuse including stimulants, cannabinoids, opiates, and alcohol. We further describe potential molecular mechanisms by which drug-induced mTORC1 activation may alter brain functions. Finally, we propose that mTORC1 is a focal point shared by drugs of abuse to mediate drug-related behaviors such as reward seeking and excessive drug intake, and offer future directions to decipher the contribution of the kinase to mechanisms underlying addiction.

image

Recent studies suggesting that exposure to diverse classes of drugs of abuse as well as exposure to drug-associated memories lead to mTORC1 kinase activation in the limbic system. In turn, mTORC1 controls the onset and the maintenance of pathological neuroadaptions that underlie several features of drug addiction such as drug seeking and relapse. Therefore, we propose that targeting mTORC1 and its effectors is a promising strategy to treat drug disorders.

Ancillary